The association between use of menopausal hormone therapy (HT) and occurrence of skin malignant melanoma (SMM) is controversial. We investigated the issue in a nationwide cohort of 684,696 Norwegian women, aged 45-79 years, followed from 2004 to 2008. The study was based on linkage between Norwegian population registries. Multivariable Poisson regression models were used to estimate the effect of HT use, different HT types, routes of administration and doses of estrogen and progestin on the risk of SMM. During the median follow-up of 4.8 years, 178,307 (26%) women used HT, and 1,476 incident SMM cases were identified. Current use of HT was associated with increased risk of SMM (rate ratios (RR) 5 1.19; 95% confidence interval (CI) 1.03-1.37). Plain estrogen therapy was associated with an increased risk of SMM (RR 1.45; 95% CI 1.21-1.73), both for oral (RR 1.45; 95% CI 1.09-1.93) and vaginal (RR 1.44; 95% CI 1.14-1.84) formulations, while combined estrogen and progestin therapy (EPT) was not (RR 0.91; 95% CI 0.70-1.19). We performed a dose-response analysis of estrogen and progestin in women using tablets, and found that use of estrogens was associated with increased risk (RR 1.24; 95% CI 1.00-1.53 per 1 mg/day) and use of progestins with decreased risk (RR 0.71; 95% CI 0.57-0.89 per 10 mg/month) of SMM. In conclusion, estrogens were associated with increased risk of SMM, while combinations of estrogens and progestins were not. Our results suggest that estrogens and progestins might affect the risk of SMM in opposite ways.
The incidence rate of skin malignant melanoma (SMM) has been steadily increasing globally in the last decades. It was estimated that SMM accounted for 232,000 new cancer cases and 55,000 deaths worldwide in 2012. 1 Known risk factors for SMM include sun exposure, fair complexion, number of nevi and freckles and family history of SMM. [2] [3] [4] Hormonal factors, both endogenous and exogenous, have been suggested to be associated with the risk of SMM. A meta-analysis of epidemiological studies published up to 2009 showed that the risk of SMM was positively associated with age at first pregnancy and inversely associated with parity. 5 A 2011 large French cohort study suggested a reduced SMM risk associated with decreased exposure to endogenous ovarian hormones, namely late age at menarche, early natural menopause and shorter ovulatory life. 6 The association between hormone therapy (HT), both oral contraceptives (OC) and menopausal HT, and SMM is controversial. The aforementioned meta-analysis reported no association of OC or HT use with SMM risk. However, a 2009 large case-control study from the Netherlands reported a strong detrimental effect of OC and plain estrogen HT on SMM risk.
between different types, routes of administration and doses of HT on the risk of SMM. In particular, we focused on the different effects of estrogen and the combination of estrogen and progestin on the risk of SMM. Information on age, education, sun exposure, parity, age at first birth, marital status and use of antihypertensives, antidiabetics, statins and thyroid therapy was used to adjust all the risk estimates.
Material and Methods

Study population
The cohort is described in detail elsewhere. 8 In short, an 11-digit unique personal identification number allowed linkage of different population-based registries. Statistics Norway and the Population Registry provided information on date of birth, emigration and death, parity, county of residence, age at first birth and education level. Redeemed prescriptions were collected from the Norwegian Prescription Database and cancer data from the Cancer Registry of Norway. The study was approved by the regional ethics committee in the South East region of Norway, and concession to data linkage was granted by the Norwegian Data Protection Authority.
We included all women born between 1925 and 1959 who were alive and residing in Norway as of January 1, 2004 (aged 45-79), n 5 800,948 (Fig. 1) . Women with a cancer diagnosis before 2004 (n 5 52,074) or who emigrated, experienced cancer or died within the first three months of followup (n 5 2,442) were excluded to ensure a minimum latency period of possible HT use. Women with prescribed sex hormones other than HT, i.e., contraceptives androgens, progestogens, female hormones in combination with androgens, gonadotropins, antiandrogens and other sex hormones were excluded in order to avoid misclassification (n 5 33,299). Finally, n 5 28,430 women with only one HT-prescription during follow-up were excluded as we assumed that such a short exposure is unlikely to affect SMM risk. Additional 7 women were excluded due to erroneous date of first birth. This left 684,696 women who were followed until December 31, 2008, any cancer diagnosis, emigration or death, whichever occurred first.
HT use and outcome
Data on HT use were collected from the Norwegian Prescription Database by retrieving all prescriptions of sex hormones in the anatomical therapeutic chemical (ATC)-groups G03C (estrogen) and G03F (estrogens and progestins in combination), redeemed from 2004 to 2008. The Norwegian Prescription Database contains detailed individual level information about all redeemed prescriptions from 2004 and onwards for the entire Norwegian population, and registration is mandatory by law. Total number of treatment days was calculated for each dispensed drug by multiplying package size by number of packages prescribed regarding the dosing intervals. For women with gaps between prescriptions, gaps shorter than 4 months were considered as continuous use, whereas longer gaps were assumed to be a stop in use with eventual re-uptake. According to their dispensed products, women were categorized as estrogen therapy (ET), tibolone (a synthetic steroid with estrogenic, progestagenic and androgenic properties) or combined estrogen-progestin therapy (EPT) users. This categorization and further categorizations according to type of combined regimen and route of administration were based on current users only. The women changing from one group to another with a gap shorter than 4 months were defined as mixed users. All EPT formulations include estradiol and norethisterone acetate as use of other progestin preparations is almost non-existent in Norway.
All women contributed person-years at risk as a non-user, current user and/or past user (Fig. 2) . A past-user was defined as women with >4 months since their last estimated use of HT. Person-years at risk within a particular category was calculated from start of study, or the date they entered the category until SMM or censoring, or the date they moved into another category. Person-year at risk as past-user was calculated from the date the estimated duration of HT ended.
The outcome was incident SMM (International Classification of Disease Seventh Revision code 190). Non-skin melanomas and non-melanoma skin cancers were not analyzed as SMM, but as censoring events.
Sun exposure
County-level information on sun exposure was extracted from the plots reported by Medhaug et al. 9 Sun exposure was expressed as the yearly sum of erythemally weighted UV radiation (ERY), a scaled version of the UV index, 10 In this study, based on the linkage of population registries in Norway, melanoma risk was found to be increased specifically by the use of estrogen-only hormone therapy. Progestin-only therapies, on the other hand, decreased risk. In addition, no association was detected between melanoma risk and hormone therapies combining estrogens and progestins. The results suggest that estrogens and progestins have contradictory effects on melanoma risk.
from the counties of Oslo, Oppland and Aust-Agder was not reported in the paper, so they were estimated using the mean of the exposures in the neighboring counties.
Statistical analysis
Incidence rate ratios (RR) with 95% confidence intervals (CI) were estimated by Poisson regression. The number of incident SMM was analyzed as a log-linear function of person-years at risk, HT use and adjusting covariates. Women were censored at death, emigration, other cancer diagnosis or at end of follow-up (December 31, 2008), whichever occurred first.
We adjusted all estimates for age in years calculated at the beginning of each exposure segment, number of births (0, 1, 2, >2), age at first birth categorized in tertiles, highest level of education (elementary, high-school, university or research level or missing), marital status (single, married/partnered, widow or divorced/separated) and use of diabetes medication (A10), antihypertensive drugs (C02, C03, C07-C09), statins (C10) and thyroid therapy (H03) as ever-use during follow-up. In addition, all models were adjusted by county-level sun exposure, categorized as low (230- The reference group in all analyses was non-use of HT except in an additional analysis to test for a statistically significant differential effect of ET and EPT use, where ET use was used as reference category. When analyzing the association of HT with a specific histological subtype (e.g., superficial spreading melanoma), only that specific subtype was analyzed as events and all other SMM were censored at the date of diagnosis. Dose-response effect of estrogen and progestin use was estimated by limiting the analysis to current users of ET and EPT tablets (oral administration) and non-users only, and retrieving the oral dose of estrogen and progestin from each prescription. The dose in non-users was set to zero. The dose of estrogen and the dose of progestin were entered in a multivariable Poisson regression model as two separate continuous variables, and were therefore mutually adjusted. Since ET and EPT users might be different, we repeated the analysis in ET users only and EPT users only, as a sensitivity analysis. We did not have information on menopausal status, and all analyses were therefore repeated for women above 55 years of age at inclusion to exclude most pre-and peri-menopausal women. All tests were two-sided. Statistical analyses were performed independently by EB, using SAS 9.4 software (SAS Institute, Cary, NC) and NCS, using R 3.3.1 software (http://cran.r-project.org/).
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Results
We followed 684,696 Norwegian women with no previous history of cancer from 2004 to 2008. During the median follow-up of 4.8 years, 178,307 (26%) used HT and 1,476 women had a diagnosis of SMM. Table 1 displays characteristics of the study population. As the cohort is very large, all differences are significant and we only mention the most important. HT users were more educated, more likely to be married or partnered, less likely to be nulliparous and more likely to have two children compared to HT non-users. HT users were more likely to use anti-hypertensives and thyroid therapies compared to HT non-users. ET users were older, resided in areas with less sun exposure and had more children compared to EPT and tibolone users. Current use of HT was associated with an increased risk of SMM as compared to non-use (incidence RR 1.19; 95% confidence interval (CI) 1.03-1.37; To avoid a possible confounding effect of menopausal status, unknown in our cohort, we repeated the analysis in women of 55 years or older at cohort entry ( Table 2) . The results remained mostly unchanged, except that the association Cancer Epidemiology between tibolone and SMM risk was now positive (RR 1.88; 95% CI 1.17-3.01; based on 18 SMM exposed cases only). ET and EPT effect on SMM according to age, education level, county-level sun exposure and age at first birth is reported in Table 3 . ET was associated with SMM risk in all age groups and education levels. ET was not associated with the risk of SMM in women living in low sun exposure areas (RR 5 1.03; 95% CI 0.64-1.66). EPT was not associated with an increased risk of SSM in any of the subgroups.
The effect of use of oral estrogens and oral progestins was analyzed in a mutually adjusted, dose-response model. Each 1 mg/day increase in oral estrogens was associated with a 24% increase in SMM risk (RR 1.24; 95% CI 1.00-1.53). Progestins showed the opposite effect, with a 29% decrease in risk for each 10 mg/month increase (RR 0.71; 95% CI 0.57-0.89). After the exclusion of EPT users, the RR associated to each 1 mg/day increase in oral estrogens was 1.23 (95% CI 0.98-1.54). After the exclusion of ET users, the RR associated to each 1 mg/day increase in oral estrogens was 1.41 (95% CI 0.82-2.44), and the RR associated to each 10 mg/month increase in oral progestins was 0.65 (95% CI 0.42-1.01). The p values for interaction between estrogen and progestin dose was 0.10 among all ET and EPT users and 0.08 in EPT users. Stratified by histological subtypes superficial, lentigo and nodular, ET was associated with superficial SMM (RR 1.37; 95% CI 1.06-1.77). There was some indication that ET was associated with increased risk of lentigo maligna and nodular SMM as well, but the number of exposed cases was low (results not shown).
Discussion
In this nationwide cohort study of 684,696 Norwegian women, we investigated the association between use of menopausal HT and the risk of SMM. We found an increased risk of SMM associated with the use of estrogens formulations (tablets and vaginal forms). Combined estrogen-progestin HT was not associated with an increased risk of SMM. When we analyzed the effect of estrogens and progestins, we found that increasing oral doses of estrogens were associated with an increased risk of SMM, while increasing oral doses of progestins were associated with a decreased risk of SMM.
Incidence of SMM is higher among women than men between the age of 20 and 45 years, but an opposite trend is observed after the age of 50, and the female reproductive life cycle has been suggested to explain this phenomenon.
11 Several epidemiological studies investigated the possible effect of endogenous sex hormones on SMM, and it was shown that the risk of SMM decreases with number of pregnancies, with older age at menarche, with younger age at first birth and with irregular menstrual cycles, early natural menopause and shorter ovulatory life. 5, 6 The impact of exogenous sex hormones on the risk of SMM was also investigated in several epidemiological studies, still it remains uncertain. A meta-analysis of 19 casescontrol studies and 6 cohort studies published up to 2009 reported no association of both OC and HT with SMM risk. 5 In particular, the authors reported a pooled relative risk, based on 7 case-control studies and 3 cohort studies, of 1.16 (95% CI 0.93-1.44) for ever versus never use of HT. No separate estimates for ET and EPT were reported in the meta-analysis, as information was not available from the original individual studies. Our estimates of ever use and current use of HT versus non-use of HT were similar to that of the meta-analysis (RR 1.12 and 1.19, respectively). We hypothesized that the lack of a clear and strong effect of HT-analyzed as a whole treatment group-on SMM risk might be due to the fact that estrogens and progestins exert opposite effects on SMM growth and progression, as it was also suggested in some in vitro studies. [12] [13] [14] [15] [16] In support of this hypothesis, when we stratified the analysis by type of HT (ET vs. EPT), we observed a increased risk of SMM by use of ET and a lack of effect in the case of EPT. In further support to our hypothesis, the dose-response analysis on hormones taken orally seemed to confirm the possible detrimental effect of estrogens and the protective effect of progestins on 17 The association between sex hormones and the risk of SMM is biologically plausible, but the mechanisms through which they exert their effect are still largely unknown. Some in vitro experiments suggested that estrogens might increase the proliferation of melanocytes and melanoma cells while progesterone might act as an anti-proliferative and pro-apoptotic agent, counteracting the stimulatory effects of estrogens. [12] [13] [14] [15] [16] Progesterone was therefore suggested to potentially act as a new anticancer agent for melanoma treatment.
14 Melanocytic lesions, including SMM, are positive for both estrogen and progesterone receptors. 12, 18, 19 Estrogen receptor beta (ERb) is the predominant estrogen receptor in melanoma cells. Its expression was reported to decrease with increasing depth of invasion and progression and therefore ERb was hypothesized to have an antitumor activity in SMM. [20] [21] [22] ERb has also been considered as a possible molecular target for melanoma treatment. A metaanalysis of nine randomized clinical trials comparing chemotherapy with Tamoxifen, which is an estrogen antagonist, to chemotherapy alone in metastatic SMM patients showed that chemotherapy with Tamoxifen improved overall and partial response, especially in women, but did not improve mortality in 1 year. 23 We found that current use of ET was associated with an increase in SMM risk, even in women using vaginal formulations. Despite their low estrogen doses, vaginal preparations can increase the estrogen levels in serum, and therefore may have a systemic effect. 24, 25 However, women using vaginal ET were different from HT non-users (e.g., they were 3 years older on average as compared to HT non-users) and the estimated impact of vaginal ET on SMM risk was possibly biased from residual confounding by uncontrolled factors. Moreover, a significant number of vaginal ET users might have used oral ET before 2004, and this possibly led to an overestimation of the effect of vaginal HT on SMM risk in our analysis.
In women of 55 years or older, tibolone users had an almost twofold increased risk of SMM. However, our result was based on 18 tibolone exposed SMM cases only. There was some association, although weak, that sequential EPT was associated with an increased risk of SMM while continuous EPT was not. One could hypothesize that this discrepancy was due to the smaller doses and number of days per month of progestins in the sequential compared to continuous EPT formulations, or that cyclic stimulation is a risk factor per se. This is the largest study on the association between HT use and SMM risk, and its main originality is given by the evaluation of a potentially different effect of ET and EPT on the risk of SMM. The registry linkages ensured detailed information on exposure of HT, including types and product information including dose of HT, and there was no recall bias as to HT used. We could retrieve information on important risk factors of SMM, such as parity and level of education. 26 There is however a number of limitations. Although this is a large cohort, the follow-up is relatively short and the statistical power might be inadequate in some subgroups. In addition, we were not able to adjust for sun exposure on an individual level, but only for sun exposure on a group level based on UV estimates according to the place of residency. This county-level sun exposure was strongly associated with SMM incidence (data not shown). Use of solarium is an establish risk factor for melanoma, as demonstrated in prospective cohort studies in Norway 27 and elsewhere. 28 Women with a positive attitude toward HT use are more likely to use solarium compared to women refusing to use HT, and this might have resulted in an overestimation of the effect of HT on SMM incidence. 29 Although our analysis might have not been adequately adjusted for sun exposure, there is no reason to suppose that sun exposure differed in ET and EPT users, thus our result on the different effect of ET and EPT on SMM risk was not likely biased. Unfortunately, we could not adjust for the complexion phenotype and family history of SMM. We do have information on ethnicity, which could have been used as a proxy for complexion, however only 1.7% of the women in our cohort was non-Norwegian, and for this reason we decided not to use this information. We lack information on smoking and height, which are two other risk factors for SMM. It is not reasonable to believe that height in itself affects HT use, however smoking may indirectly influence HT use as smokers tend to be less concerned about their health. In addition, our estimates could be affected by the healthy user bias: it is possible that HT users were more concerned about their health than non-users and, for example, underwent more skin examinations and removals of precancerous lesions. This could have led to an underestimation of the effect of ET on SMM risk. As a proxy for the general health, we adjusted all analyses for use of other available medications: antihypertensives, antidiabetics, statins and thyroid therapy. We also chose to censor non-melanoma skin cancer cases as their behavior, especially behaviors related to melanoma risk, such as sun exposure and awareness toward skin cancer, changes after such a diagnosis. Finally, we did not have information on menopausal status. Nonetheless, the sensitivity analysis excluding women below age 55 years to avoid a possible confounding effect of menopausal status confirmed the results obtained in the main analysis.
In conclusion, estrogen menopausal HT was associated with an increased risk of SMM, while the combined estrogen-progestin HT was not. Increasing oral dose of estrogens was associated with an increased risk of SMM while for oral progestins the risk of SMM decreased with increasing dose. There is a need for more studies for understanding the effects of sex hormones on SMM, including types of hormones and types of regimens.
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